Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1631 1633 1643 1651 1798
This examiner grants 51% of resolved cases
Arthur S. Leonard has resolved 519 cases in Art Unit 1631. The examiner has an allowance rate of 50.7 percent. This 50.7 percent rate is based on the 519 resolved cases in Tech Center 1700. Practitioners can use these figures to evaluate the probability of a grant. The volume of resolutions provides a specific data set for this examiner's history.
The interview lift is 50.1 percent. This 50.1 percent figure represents the change in the allowance rate when an interview is conducted. Practitioners should consider this lift when deciding on a prosecution strategy. This metric indicates how interviews correlate with the overall allowance rate. The 50.1 percent lift is a recorded factor in the examiner's prosecution profile.
The median time to allowance is 1260 days. This 1260 day duration is the middle value for the time from filing to grant. Applicants can use this figure to plan their prosecution timelines. The median pendency is a specific temporal measure in Art Unit 1631. It provides a benchmark for cases assigned to this examiner. Understanding this 1260 day timeline is important for managing expectations during the examination process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18980456 | Targeted CRISPR Delivery Platforms | Non-Final OA | University of Massachusetts |
| 18612111 | Targeted CRISPR Delivery Platforms | Non-Final OA | University of Massachusetts |
| 18049724 | COMPLEXES FOR GENE DELETION AND EDITING | Final Rejection | UNIVERSITY OF MASSACHUSETTS |
| 18372374 | METHOD OF PRODUCING A CELL POPULATION COMPRISING AN AMNION-DERIVED MESENCHYMAL STEM CELL | Final Rejection | KANEKA CORPORATION |
| 17933005 | METHODS FOR MODIFICATION OF TARGET NUCLEIC ACIDS | Final Rejection | BASF Plant Science Company GmbH |
| 17933023 | METHODS FOR MODIFICATION OF TARGET NUCLEIC ACIDS | Final Rejection | BASF PLANT SCIENCE COMPANY GMBH |
| 17865375 | Programmable Modification of DNA | Final Rejection | Massachusetts Institute of Technology |
| 17831745 | DELIVERY, USE AND THERAPEUTIC APPLICATIONS OF THE CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR GENOME EDITING | Final Rejection | Massachusetts Institute of Technology |
| 17433887 | ADENO-ASSOCIATED VIRUS VECTORS FOR THE DELIVERY OF THERAPEUTICS | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18484667 | METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION | Final Rejection | THE TEXAS A&M UNIVERSITY SYSTEM |
| 18578856 | ENGINEERED S. TYPHIMURIUM AND USES THEREOF | Non-Final OA | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. |
| 17278866 | SSI CELLS WITH PREDICTABLE AND STABLE TRANSGENE EXPRESSION AND METHODS OF FORMATION | Non-Final OA | PFIZER, INC. |
| 18515493 | Method and Apparatus for High Throughput High Efficiency Transfection of Cells | Non-Final OA | The Charles Stark Draper Laboratory, Inc. |
| 18670290 | COMPOSITIONS AND METHODS FOR TREATING B-LYMPHOID MALIGNANCIES | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18981653 | TISSUE-SELECTIVE SINGLE-COMPONENT MRNA DELIVERY CARRIER AND DELIVERY SYSTEM | Non-Final OA | INSTITUTE OF PROCESS ENGINEERING , CHINESE ACADEMY OF SCIENCES |
| 17725982 | ASSAY AND MEDICAMENT | Non-Final OA | The University of Warwick |
| 18662315 | ANTIGEN-BINDING PROTEINS TARGETING CD56 AND METHODS OF PRODUCING THEREOF | Non-Final OA | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE |
| 18276567 | PROCESS FOR THE PURIFICATION OF MONOCLONAL ANTIBODIES | Non-Final OA | LUPIN LIMITED |
| 18268734 | COMPOSITION FOR SKIN IMPROVEMENT, CONTAINING CULTURE LIQUID OF UMBILICAL-CORD-DERIVED MESENCHYMAL STEM CELLS AS ACTIVE INGREDIENT | Non-Final OA | HANS PHARMA CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy